National Comprehensive Cancer Network



About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Clinical Practice Guidelines in Oncology™ for Non-Hodgkin's Lymphomas and Prostate Cancer Have Been Updated and Published as Version 1.2010

Updates to the NCCN Guidelines for NHL include a new guideline for Adult T-Cell Leukemia/Lymphoma. For follicular lymphoma, bendamustine with rituximab was added as a first-line treatment option and for mantle cell lymphoma, bendamustine with or without rituximab was added as a less aggressive induction treatment option. Treatment recommendations for rare lymphoma types, primary mediastinal B-cell lymphoma and NK/T-cell lymphoma, were also added.

Updates to the NCCN Guidelines for Prostate Cancer include recommendations that men with low risk prostate cancer who have a life expectancy of less than 10 years should be offered and recommended active surveillance. In addition, a new "very low risk" category has been added to the updated NCCN Guidelines for clinically insignificant prostate cancer and only active surveillance is offered and recommended for men in this category when life expectancy is less than 20 years. For patients with locally advanced, very high risk disease, a recommendation for short term neoadjuvant/concomitant/adjuvant ADT (4 – 6 months) was changed to long term ADT (2 – 3 years). A new page for Systemic Salvage Therapy for Castration-Recurrent Prostate Cancer was added to the guideline. A new section on palliative radiotherapy was added to Principles of Radiation Therapy.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, and the NCCN Chemotherapy Order Templates™ please visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved